Replies to post #99112 on Biotech Values

[genisi]

Once-daily Kaletra was approved end of Apr for treatment in experienced patients, so the downfall might slow a bit. Reyataz is already the leading PI and Prezista is a tough competitor but I think Isentress might be less of a competitor due to low barrier to resistance. On the big picture I agree with ciotera - the trend is not in favor for Kaletra.